Each of two rewrites in this neutropenic fever case answers a named finding, a halo sign with a positive galactomannan and then a toxic [voriconazole] trough, in NU652's Unit 10. Searches like "nu 652 unit 10 assignment example", "nu652 unit 10 sample" and "nu652 unit 10 example" land here.
What a finished NU652 Unit 10 management revision case study looks like
Eight pages arranged as three dated plans, each followed by the finding that ended it. Plan one, on the first night of fever, follows the IDSA febrile neutropenia guideline: blood cultures from each catheter lumen and a peripheral site, [cefepime] at a bracketed dose, and a stated reassessment at [72] to [96] hours. Day [four] brings a temperature of [102.2] F with negative cultures and an absolute neutrophil count of [100]; a CT shows two nodules with a surrounding halo, and serum galactomannan returns an index of [1.8]. Plan two adds [voriconazole] for probable invasive aspergillosis, keeps [cefepime], and requests bronchoscopy if he can tolerate it. Day [seven] records visual hallucinations and a trough of [7.4] mcg/mL. Plan three switches to [isavuconazole], stops [voriconazole], and schedules a repeat CT. A reflection page follows each revision.
How a NU652 Unit 10 example is structured
Each revision is presented as a before-and-after pair, showing exactly what was stopped, what continued and what began. The finding that ended each plan is quoted with its value and set in bold. The first revision is framed by the question persistent neutropenic fever forces: a resistant bacterium, a hidden source or a fungus? The paper works through each and explains why the CT and galactomannan tip it toward mold, citing the IDSA aspergillosis guideline (Patterson and colleagues, 2016) for [voriconazole] as primary therapy. The second revision is a toxicity problem rather than a diagnostic one. It ties the hallucinations to the trough, cites the SECURE trial (Maertens and colleagues, 2016) for [isavuconazole] as a noninferior alternative with fewer adverse events, and keeps [cefepime] running until count recovery. Each reflection page stays under [200] words.
Three plans, each dated
First fever, day [four] and day [seven] each carry a complete plan rather than a list of changes. Reading any one of them shows the full management in force at that moment.
The question persistent fever asks
Resistant organism, occult source, drug fever or fungus: the paper tests all four against the cultures, the line sites and the scan before choosing. The ranking is visible rather than assumed.
Evidence for mold, weighed
A halo sign and a galactomannan index of [1.8] make aspergillosis probable, not proven. The paper uses that word deliberately and explains what bronchoscopy could add.
A second revision of a different kind
Hallucinations on day [seven] do not reopen the diagnosis; they reopen the drug. Naming that distinction keeps the case from treating every change as the same move.
Antibacterial coverage kept
[Cefepime] continues through both revisions until the neutrophil count recovers. The paper states why stopping it would be premature even with a fungal diagnosis in hand.
Where marks go in NU652 Unit 10
A case study of this kind is read as a sequence, and marks fall where a revision appears without the finding that forced it. Papers that add an antifungal on day [two] without a stated reason, or that broaden antibacterials on day [four] without asking what else the fever could be, skip the reasoning this case study exists to show. Treating a positive galactomannan as proof of aspergillosis draws a correction, as does ignoring the halo sign's place in the evidence. Stopping [cefepime] once the fungal diagnosis appears is an error graders treat seriously in neutropenia. The toxicity revision is judged on linking the level to the symptoms and justifying the replacement with trial evidence. Earlier plans silently edited rather than preserved suggest the exercise was misread, and reflection pages that merely restate events add little.
Get a NU652 Unit 10 example written to your instructions
Final-unit cases vary by section, from a single patient supplied in the prompt to one the student constructs. Either kind works: share the case or its outline, how many revisions are expected, and the rubric. A first case study at no cost, returned within 24-48h, preserves each earlier plan intact beside the finding that ended it.
NU652 Unit 10 questions, answered
Why keep the earlier plans instead of presenting only the final one?
Because the assignment is about revision. What was believed at each point, and what changed it, has to stay visible; a final plan alone hides the reasoning. The sample preserves every plan as written on its date and places the ending finding beneath it, which is also how an acute care chart ideally reads when a diagnosis evolves.
Is isavuconazole the only alternative to voriconazole?
No. [Liposomal amphotericin B] and [posaconazole] both appear in current guidance as alternatives, each with its own toxicity and interaction profile. [Isavuconazole] is chosen for this composite because of the SECURE trial data and its milder adverse event profile, but your case, its drug interactions and the local formulary may point to a different agent.
How many revisions should the case contain?
Whatever your prompt specifies; two is common. Each revision should follow a distinct finding rather than a gradual adjustment of the same plan. The sample's two rewrites respond to different kinds of problem, a new diagnosis and then a drug toxicity, which lets it show two different reasoning moves in one admission instead of repeating the first.